Quick answer
Published hexarelin research is preclinical and clusters in four areas: receptor identification (GHS-R1a and the scavenger receptor CD36), cardiac models (isolated hearts, coronary ligation, hypertensive rats), metabolic models (insulin-resistant and obese mice, streptozotocin-diabetic rats) and cell lines. Reported outcomes include preserved cardiac function in ischemia models, reduced collagen deposition in hypertensive rat hearts, and altered lipid and glucose readouts in mice. Most come from a small number of laboratories and disease models with varied schedules, so the evidence is hypothesis-generating. For laboratory research use only; not for human consumption.
Hexarelin has been studied for more than three decades, but the literature is not one story. It is a set of separate model systems, each designed to answer a narrow question, and a reader who merges them gets a distorted picture. This review organizes the primary papers by model system and states, for each, what the design can establish and what it cannot. It reports what the authors found in animals and cells and draws no conclusion about people. The material is the research reagent on the hexarelin product page; the structural and receptor background is in the hexarelin research overview and what is hexarelin.
Map of the evidence
| Model system | Representative papers | Question the design answers | Main limit |
|---|---|---|---|
| Receptor identification | Bodart and colleagues, 2002 | What binds hexarelin in heart tissue? | Binding and perfusion pressure; not a disease outcome |
| Isolated perfused hearts and cardiomyocytes | Ma and colleagues, 2012; Locatelli and colleagues, 1999 | Does hexarelin change ischemia-reperfusion injury outside the whole animal? | Ex vivo; no circulation, no hormone feedback |
| Rodent cardiac disease | Tivesten and colleagues, 2000; Huang and colleagues, 2017; Xu and colleagues, 2012; Mao and colleagues, 2014 | Does hexarelin change cardiac function, fibrosis or remodeling? | Surgical or genetic models; small cohorts; few independent labs |
| Metabolic models | Mosa and colleagues, 2017; Huang and colleagues, 2021; Zhang and colleagues, 2018 | Does hexarelin change lipid, glucose or GH readouts? | Specific genetic or chemical models of disease |
| Cell-line injury | Zhao and colleagues, 2016 | Does hexarelin protect cultured beta cells from a toxin? | One toxin, one cell line; translation unknown |
The five rows differ in species, tissue, and the type of question. A positive result in any one row does not carry over to the others, and the sections below keep them separate.
Receptor biology: GHS-R1a and CD36
Hexarelin was designed as a growth hormone secretagogue, and its pituitary actions run through GHS-R1a. The cardiac literature raised the question of whether the heart effects use the same receptor. Bodart and colleagues labelled rat cardiac membranes with a radioactive photoactivatable hexarelin derivative, purified the bound protein and found a binding protein of about 84 kDa whose N-terminal sequence matched rat CD36. In perfused hearts, hexarelin raised coronary perfusion pressure in a dose-dependent way, and that response was absent in hearts from CD36-null mice and from spontaneously hypertensive rats genetically deficient in CD36 (Bodart and colleagues, 2002).
This is the foundation for the statement, now common, that hexarelin acts at more than one receptor. Two cautions: the experiment shows binding and a vascular pressure response, not that CD36 mediates every cardiac effect reported elsewhere; and later papers still invoke GHS-R1a, as when a GHS-R antagonist abolished hexarelin's effects in hypertensive rats (Xu and colleagues, 2012). The two receptors are both in play, and different readouts depend on different ones.
Isolated heart and cardiomyocyte studies
Locatelli and colleagues gave hypophysectomized rats hexarelin at 80 µg/kg subcutaneously for seven days and then tested the isolated hearts. Hexarelin prevented the worsening of ischemia-reperfusion damage that hypophysectomy produced, including increases in left ventricular end-diastolic pressure and creatine kinase release, whereas a second GH-releasing peptide that does not bind the heart was ineffective. The authors concluded that the action was not mediated by GH and likely involved specific cardiac receptors (Locatelli and colleagues, 1999).
Ma and colleagues perfused mouse hearts with 1 nM hexarelin before or after 20 minutes of global ischemia. Both pre- and post-exposures prevented the fall in cell shortening, intracellular calcium transient amplitude and sarcoplasmic reticulum calcium content after reperfusion, with recovery of phospholamban phosphorylation as the proposed mechanism (Ma and colleagues, 2012). Because the hearts were removed from the animal, these results separate a direct cardiac action from systemic hormone effects, which is the point of the design.
Rodent cardiac disease models
Four in vivo papers cover different cardiac questions:
- Remodeling after coronary ligation. Rats exposed subcutaneously for two weeks with hexarelin at 10 or 100 µg/kg per day, starting four weeks after ligation, showed higher stroke volume and cardiac output at the higher quantity, comparable to recombinant GH given for comparison (Tivesten and colleagues, 2000). Body weight gain rose with GH but not with hexarelin.
- Ischemia-reperfusion in the living animal. In rats exposed for seven days, hexarelin improved systolic function, reduced malondialdehyde and increased surviving cardiomyocytes, with down-regulation of IL-1β and up-regulation of IL-1 receptor antagonist reversed by a GHS-R antagonist (Huang and colleagues, 2017).
- Fibrosis in hypertensive rats. Five weeks of hexarelin reduced collagen deposition and hydroxyproline content, lowered collagen I and III expression, raised MMP-2 and MMP-9 activity and lowered TIMP-1 mRNA, and an antagonist abolished the effect (Xu and colleagues, 2012). The authors note that lower blood pressure may also contribute.
- A single oral exposure. One dose by gavage 30 minutes after coronary ligation in mice was followed by higher ejection fraction and fractional shortening at the chronic stage, with lower plasma epinephrine and dopamine and a shift in autonomic balance (Mao and colleagues, 2014).
These studies agree in direction, but they share features that limit inference: surgical models with variable infarct size, small groups, and, in several cases, the same research groups. None has been independently replicated in the sense of a multi-site design.
Metabolic models
Three papers address metabolic readouts:
| Paper | Model | Reported findings |
|---|---|---|
| Mosa and colleagues, 2017 | Non-obese insulin-resistant MKR mice, 200 µg/kg intraperitoneal twice daily for 12 days | Improved glucose and insulin tolerance; lower plasma and liver triglycerides; lower fat mass and higher lean mass; food intake rose without a change in body weight |
| Huang and colleagues, 2021 | Obese MC4RKO mice on osmotic pump, 3–4 weeks | Pulsatile GH increased; lipolysis and lipid oxidation in adipose tissue rose; hepatic lipogenesis and liver triglyceride fell; whole-body insulin sensitivity improved without change in glucose tolerance or IGF-1 |
| Zhang and colleagues, 2018 | Streptozotocin-diabetic rats, daily for 2 weeks | Impaired pulsatile GH normalized; fasting free fatty acids fell; IGF-1 remained suppressed |
The Mosa paper notes earlier reports that hexarelin affects fat metabolism through CD36, the receptor identified in the heart, and the Huang mouse paper attributes the metabolic effects to GH action on fat and liver. Taken together the models suggest two routes, one through GH and one more direct, but the studies were not designed to separate them. The IGF-1 findings are examined in a separate article on hexarelin and IGF-1 in preclinical studies.
Cell-line protection models
Zhao and colleagues used a mouse beta-cell line (MIN6) challenged with streptozotocin. Hexarelin at 1.0 µM decreased the toxin-induced damage, ameliorated mitochondrial damage and superoxide, and reduced cleaved caspase-3 and caspase-9 and the Bax/Bcl-2 ratio. In a streptozotocin rat model, hexarelin also preserved plasma insulin and islet structure (Zhao and colleagues, 2016). The design shows that hexarelin can modify a toxin-driven injury pathway in these cells; it does not show relevance to any other injury.
How strong is the evidence?
A practical reading uses four questions: is the finding reproducible across laboratories, does it appear in more than one species, is the dose-response or concentration-response described, and was the mechanism tested with a blocker or knockout?
| Finding | Multiple labs | Multiple species | Mechanism tested |
|---|---|---|---|
| CD36 as a cardiac binding protein | Limited | Rat, mouse (null hearts) | Yes (null hearts) |
| Reduced ischemia-reperfusion injury in heart | Several | Rat, mouse | Yes (antagonist, hypophysectomy) |
| Reduced cardiac fibrosis | One group in the cited set | Rat | Yes (antagonist) |
| Metabolic and lipid changes | Few | Mouse, rat | Partly |
| Beta-cell protection | One group | Mouse cell line, rat | Pathway markers |
By this measure the cardiac ischemia-reperfusion result is the best supported and the beta-cell and fibrosis results are single-group findings that need independent confirmation.
Using the literature in study design
A laboratory choosing hexarelin as a tool should match its model to the closest published design, state the species, schedule and route as in the source paper, and include the controls those papers used, such as a vehicle group and a GHS-R antagonist arm. Concentration math for stock solutions is covered in the reconstitution calculator and the calculator guide, and comparisons with other secretagogues in hexarelin vs GHRP-6 and hexarelin vs GHRP-2. Material quality should be documented from the lot's certificate where one has been published on the COA page.
Related reading
- Hexarelin research overview
- What is hexarelin?
- Hexarelin vs GHRP-6
- Hexarelin vs GHRP-2
- Hexarelin vs ipamorelin
- Research peptide catalog
Frequently asked questions
What kinds of preclinical studies exist for hexarelin?
Receptor-identification work, isolated-heart and cardiomyocyte experiments, rodent models of cardiac injury and fibrosis, metabolic studies in mice and rats, and cell-line injury models.
Which receptors does hexarelin act on in the research literature?
GHS-R1a, the ghrelin receptor, and the scavenger receptor CD36, which was identified as a cardiac binding protein in rat heart membranes.
Is the hexarelin cardiac evidence strong?
The ischemia-reperfusion findings appear in rats and mice and are supported by antagonist or knockout controls, making them the best supported area. The fibrosis finding comes from one group in the cited set.
Did hexarelin effects require growth hormone in the animal studies?
Not always. In hypophysectomized rats hexarelin protected isolated hearts, and the authors described the effect as GH-independent. Metabolic effects in obese mice were attributed to GH action.
What are the main limits of the hexarelin literature?
Small groups, disease-specific models, varied schedules and routes, and limited independent replication. Abstracts also omit details, so full methods are needed for replication.
Can these results be used to make claims about people?
No. They describe animals and cells. Hexarelin is supplied for laboratory research use only.
How should a lab choose a model for hexarelin?
Match the closest published design, state species, schedule and route, and include vehicle and receptor-antagonist controls as in the source studies.
Related reading: Hexarelin Lab Applications: Assays and Model Systems, Hexarelin Research Profile: Chemistry and Key Studies, Hexarelin Side Effects in Research: What Studies Report.
References
- Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, et al.. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-9. doi:10.1161/01.res.0000016164.02525.b4
- Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, et al.. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-31. doi:10.1210/endo.140.9.6948
- Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C. Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One. 2012;7(4):e35265. doi:10.1371/journal.pone.0035265
- Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, et al.. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology. 2000;141(1):60-6. doi:10.1210/endo.141.1.7249
- Huang J, Li Y, Zhang J, Liu Y, Lu Q. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. Int Heart J. 2017;58(2):257-263. doi:10.1536/ihj.16-241
- Xu X, Ding F, Pang J, Gao X, Xu RK, Hao W, et al.. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2012;303(6):H703-11. doi:10.1152/ajpheart.00257.2011
- Mao Y, Tokudome T, Kishimoto I, Otani K, Miyazato M, Kangawa K. One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Peptides. 2014;56:156-62. doi:10.1016/j.peptides.2014.04.004
- Mosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, et al.. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017;158(10):3174-3187. doi:10.1210/en.2017-00168
- Huang Z, Lu X, Huang L, Zhang C, Veldhuis JD, Cowley MA, et al.. Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice. FASEB J. 2021;35(1):e21269. doi:10.1096/fj.202001924RR
- Zhang X, Yang JK, Chen C. Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats. Int J Mol Sci. 2018;19(10):. doi:10.3390/ijms19103067
- Zhao Y, Zhang X, Chen J, Lin C, Shao R, Yan C, et al.. Hexarelin Protects Rodent Pancreatic Β-Cells Function from Cytotoxic Effects of Streptozotocin Involving Mitochondrial Signalling Pathways In Vivo and In Vitro. PLoS One. 2016;11(2):e0149730. doi:10.1371/journal.pone.0149730
